MA-IBASIS
14.5.2024 14:01:39 CEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Altice Dominicana, one of the leading mobile networks in the Dominican Republic, announced today that they have renewed their successful outsourcing agreement for voice services.
Since its sale by Altice in 2018, iBASIS and its global team have been dedicated to bringing Altice Dominicana best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. iBASIS has helped to drive the Dominican operator’s performance, monetization, and profitability through its differentiated model, international expertise, and exclusive Inbound Gateway. Key focus areas, including cost improvement and fraud prevention, have also played a pivotal role in supporting Altice Dominicana’s sustained traffic growth.
“iBASIS demonstrated their commitment to deliver value across many facets of our international business. Their offerings and expertise, specifically in addressing international requirements, enable us to make significant service quality enhancements and cost improvements,” said Jennifer Espinal, International Business Manager at Altice Dominicana. “The strategic relationship, including the exclusive Inbound Gateway, is essential for maintaining our growth trajectory and securing our leading position in the region. We are also fortifying this collaboration and expanding into mobile services in order to capitalize on the growth of inbound roaming traffic.”
The Dominican Republic has experienced remarkable growth in tourism, witnessing a 14% increase in international visitors in 2023 compared to 2019, surpassing 10 million travelers for the first time.* Ensuring excellent roaming performance and experience is crucial in such an appealing destination for foreign visitors.
“With Altice Dominicana, we share the same goal of providing state-of-the-art connectivity and supporting innovations to unleash the potential of international communications,” said Edwin van Ierland, CEO of Voice & Mobile Data at iBASIS. “Thanks to our global platforms, capabilities, and highly motivated teams, iBASIS is a high-growth partner and is helping Altice Dominicana to continue to perform at the highest level.”
“The renewal with Altice Dominicana marks another significant milestone, highlighting the appeal of iBASIS's outsourcing proposition," remarked Alexandre Pébereau, Group CEO and Founder of Tofane Global. "By overseeing the entire spectrum of international voice and mobile communications for them, our customers can concentrate on their retail business, foster growth, and sustain their dominant market position.”
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. For more information, please visit iBASIS.com.
ABOUT Altice Dominicana
Altice Dominicana is one of the main telecommunications companies in the Dominican Republic, with a decade-long history of offering connectivity and entertainment services.
Its robust mobile network has 98% coverage nationwide; With an extensive fiber optic network infrastructure, it provides Internet with the highest speed available on the market, up to 1,000 MB, cable television and high definition voice services to more than 4 million homes and businesses throughout the country.
Through its human team, agile, with challenging and daring thinking, it promotes innovation in everything it does and demonstrates its commitment to each of the Dominicans in providing them with access to technology to boost their growth opportunities.
*2023 Global Travel Trends Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514293879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom